Clexio

Clexio is a multi-asset, clinical-stage pharmaceutical company focused on CNS with a broad and growing pipeline. Clexio is committed to developing new therapies for patients with neurological and psychiatric disorders. Clexio is advancing novel treatments to address unmet needs in patients with major depressive disorder, neurogenic chronic itch, neuropathic pain, cluster headache, and Parkinson’s disease.